The role of isocitrate dehydrogenase mutations as a therapeutic target for cancer therapy is examined.
No takes yet. Share an insight, caveat, or question.
Yen et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: